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Abstract 
Background: Stem cell-based therapies for neurodegenerative diseases like Parkinson’s disease are a promising 
approach in regenerative medicine and are now moving towards early stage clinical trials. However, a number of chal-
lenges remain including the ability to grow stem cells in vitro on a 3-dimensional scaffold, as well as their loss, by leak-
age or cell death, post-implantation. These issues could, however, be helped through the use of scaffolds that support 
the growth and differentiation of stem cells both in vitro and in vivo. The present study focuses on the use of bacterial 
cellulose as an in vitro scaffold to promote the growth of different stem cell-derived cell types. Bacterial cellulose was 
used because of its remarkable properties such as its wettability, ability to retain water and low stiffness, all of which is 
similar to that found in brain tissue.
Methods: We cultured human embryonic stem cell-derived progenitor cells on bacterial cellulose with growth fac-
tors that were covalently functionalised to the surface via silanisation. Epifluorescence microscopy and immunofluo-
rescence were used to detect the differentiation of stem cells into dopaminergic ventral midbrain progenitor cells. We 
then quantified the proportion of cells that differentiated into progenitor cells and compared the effect of growing 
cells on biofunctionalised cellulose versus standard cellulose.
Results: We show that the covalent functionalisation of bacterial cellulose sheets with bioactive peptides improves 
the growth and differentiation of human pluripotent stem cells into dopaminergic neuronal progenitors.
Conclusions: This study suggests that the biocompatible material, bacterial cellulose, has potential applications in 
cell therapy approaches as a means to repair damage to the central nervous system, such as in Parkinson’s disease but 
also in tissue engineering.
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Introduction
One major area of regenerative medicine includes the 
use of stem cells, progenitor cells or tissue transplants 
to restore the physiological function of diseased tissue 
through either (1) direct cell replacement, (2) by provid-
ing trophic support to the remaining host cells and matrix 
or (3) by modulating aspects of the local environment 
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such as the immune response to the diseased tissue [30]. 
Early stage clinical trials are currently emerging in the 
field of neurodegeneration [27, 28, 44]. For example, in 
Parkinson’s disease (PD), trials are under way to use stem 
cells to replace lost nigral dopaminergic neurons that lie 
at the heart of the symptoms observed in PD patients [15, 
32, 33]. In these trials, PD patients receive transplants of 
human foetal ventral mesencephalic cells into the stria-
tum as a means to replace the lost dopaminergic innerva-
tion of the striatum which can lead to long-lasting relief 
of clinical features of PD patients [13, 27, 28, 30, 48]. 
However, the use of foetal tissue is associated with major 
logistical and ethical problems which may be solved by 
using human pluripotent stem cells instead. Human 
pluripotent stem cells are extracted from left-over early-
stage embryos following infertility treatment which, after 
informed consent, can be donated to medical research 
[34].
Human embryonic stem cells (hESCs) are pluripotent 
stem cells derived from the inner cell mass of blasto-
cysts and have the ability to differentiate into different 
cell lineages under appropriate culture conditions. Pro-
tocols have been developed to differentiate ESCs into 
precursors of multiple cell types including dopaminergic 
neurons affected in PD [25, 37]. However, despite these 
successes there are several key challenges in taking such 
therapies forward to larger-scale clinical trials including 
their directed differentiation and survival pre- and post-
implantation [30]. One strategy to try and better sup-
port transplanted cells would be through the use of an 
implantable biodegradable scaffold that aids adhesion of 
cells.
Cell scaffolds provide a three-dimensional biomimetic 
environment that supports the culture and growth of 
cells and tissue; ideally, these scaffolds should (1) contain 
a highly porous and permeable matrix in which nutri-
ents and metabolic waste can be exchanged during cell 
growth, (2) be biocompatible, biodegradable and chemi-
cally tuneable to permit surface modification to guide 
cell adhesion and differentiation and (3) have mechani-
cal properties that closely match the tissue at the site of 
implantation in order to increase cell integration and to 
decrease the chance of tissue rejection [14].
Numerous implantable scaffolds have been investigated 
in order to match the mechanical and physiological prop-
erties of the local tissue. Chitosan, a biopolymer made 
by alkaline N-deacetylation of chitin, has also been used 
as a neural scaffold due to its biocompatibility, low tox-
icity and low cost [9]. However, as a material, chitosan, 
with a Young’s modulus of 3–10  kPa, is far more rigid 
than brain tissue [47], with a Young’s modulus of 0.2–
0.8 MPa (Fig. 1D)[8]. The same is true for PDMS (poly-
dimethylsiloxane), a material commonly used for in vivo 
microfluidic cell devices, which has been used success-
fully in 3D cultures of primary hippocampal neurons 
[26]. However, besides being stiffer than brain tissue (10: 
1 base to crosslinker, 580 kPa), PDMS also requires addi-
tional coating to reduce its hydrophobicity [38]. Thus, 
as the tools and techniques for stem cell differentiation 
and cell growth improve, there is a continuous need for 
matrix material that can act as a cellular scaffold and 
matches the material properties of the surrounding brain 
tissue. Herewith, we describe the use of bacterial cellu-
lose as a suitable cell scaffold material.
Cellulose is the most abundant biopolymer in nature, 
and bacterial cellulose (BC), in particular, has attracted 
much interest in the material science community as it 
is produced using ecologically sustainable strategies and 
has several advantages over plant cellulose. Although BC 
and plant cellulose have the same chemical structure of 
 (C6H10O5)n, BC has higher purity, and its well-spaced 
nano- and microfibrils result in higher strength, mould-
ability and increased water capturing ability compared to 
plant cellulose [11, 19]. The Gluconacetobacter hansenii 
bacterial strain is most widely used for BC production 
due to its high yield. These bacteria often produce cellu-
lose as a part of a stress response, because in the absence 
of oxygen, BC is usually produced as a 1% w/v thin film 
that rises to the air–liquid interface carrying aerobic bac-
teria as the source of oxygen [24, 45].
The unique cellulose structure is produced when hun-
dreds-to-thousands of cellulose chains are extruded from 
pores on the bacterial cell envelope. These chains first 
combine into microfibrils through hydrogen bonding 
and further into cellulose ribbons that make up the mac-
rostructure of cellulose pellicles [45]. A cellulose sheet, 
which is a well-spaced 3D mesh of ribbons, is highly 
porous (Fig.  1A). These cellulose sheets can be dehy-
drated by freeze-drying to improve the shelf life and for 
further modification (Fig. 1C).
The biocompatibility, vapour permeability, mould-
ing ability, structural integrity and high water capturing 
capability make BC highly suitable for medical applica-
tions such as wound dressing, tissue engineering and 
guided tissue regeneration [10]. Furthermore, ribbons 
of bacterial cellulose microfibrils are structurally simi-
lar to native extracellular matrices produced by mam-
malian cells [11]. In addition, BC is composed of nearly 
100% cellulose only and thus does not contain any addi-
tional polymeric and small molecule components, mak-
ing it easier to purify and characterise unlike many other 
biopolymers including plant-based cellulose [32, 33]. 
Both the structural arrangement of BC and the absence 
of other molecular components may thus explain why BC 
has not been found to evoke an immune response from 
in vitro and in vivo studies [16, 22, 23, 35].
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For tissue engineering and regeneration, cell scaffolds 
are often used to support cell integration by providing 
an interface for cells whilst they form cell–cell con-
nections and their own extracellular matrix. The use 
of BC has already been shown to provide a monolayer 
of fibroblasts and/or keratinocytes that can be directly 
placed into wounds to promote tissue regeneration. 
In these cases, BC is soaked in serum and electrolytic 
solutions such as sodium hydroxide or adsorbed in col-
lagen to promote cell adhesion [10, 51].
Various composites of BC and other materials such 
as graphene have also been assembled to enable stem 
cell differentiation into various cell lines including neu-
rons. Particularly exciting is the use of BC scaffolds for 
the growth of neurons [26]. The ability to grow neu-
rons on BC cellulose is highly advantageous due to its 
increased biocompatibility and reduced rigidity. Along-
side this, BC has a similar stiffness to brain, of around 
7 kPa [36], and more robust mechanical properties and 
Fig. 1 Bacterial cellulose sheets are made by cellulose chains produced by bacteria. A Bacterial cellulose initially forms cellulose chains that 
through hydrogen bonding turn into microfibrils which consequently form larger, well-spaced ribbons/nanofibres and ultimately cellulose sheets. B 
The repeated monomeric structure of cellulose then forms a cellulose chain. C A piece of freeze-dried cellulose sheet after overnight dehydration. D 
BC is most similar in stiffness to the brain as compared to other commonly used biomaterials for fabrication of medical devices. Furthermore, BC is 
highly biocompatible and therefore is an optimal material for the fabrication of prosthetics that require moulding to brain regions
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thermostability compared to other naturally derived 
polymers including matrigel, collagen and silk (Fig. 1D) 
[52].
In addition to its inherent properties, additional func-
tionalities can be introduced by BC modification, for 
example, by activation of bioactive peptides or small 
molecules. The biofunctionalisation of stem cell scaffolds 
using growth factors (GFs) has previously been shown to 
enhance stem cell differentiation or improve their func-
tionality [5, 22, 23, 39]. The presence of GFs within the 
scaffold removes the need for further injection of GFs 
after the cells have been implanted and also circumvents 
the challenge of getting such factors across the brain–
blood barrier.
In order to design a functional and biocompatible stem 
cell and neuronal scaffold, we have investigated bacterial 
cellulose covalently modified with growth factors BDNF 
(brain-derived neurotrophic factor) and GDNF (glial 
cell-derived neurotrophic factor). Directed differentia-
tion of progenitor cells using BDNF has been previously 
investigated [7, 18, 20, 31, 40, 54]. Recently, Horne et al. 
used aminolysation of BDNF onto nanofibre scaffolds as 
a means to direct progenitor cells towards differentiation 
into oligodendrocytes and neurons [18]. However, they 
employed a polycaprolactone polymer, which degrades 
slowly over time, has poor cell adhesion, wettability and 
mechanical properties with a stiffness of 50  MPa [53]. 
The latter is more commonly used for bone tissue engi-
neering, making it less suitable for softer brain tissue 
implantation. GDNF is another neurotrophic factor that 
has been shown to improve the survival and plasticity of 
dopaminergic neurons in vitro and following transplanta-
tion [2, 12, 21, 29, 49]. GDNF delivery through hydrogel 
scaffolds has previously been shown to increase regen-
eration and nerve repair [46], and pre-treatment of pro-
genitor cells with GDNF improves cell survival following 
transplantation in a rodent Parkinson’s disease model [2, 
6].
We therefore sought to investigate the use of BDNF- 
and GDNF-modified BC sheets as a scaffold for neu-
ronal progenitor cells. As a first step, we showed that the 
adhesion of ES-derived progenitor cells to the cellulose 
membrane was sufficient to ensure sufficient growth, as 
this has not previously been shown for neural progenitor 
cells. As a next step, we showed that a biofunctionalisa-
tion method previously used on cellulose nanoparticles 
could also be used optimally for use on cellulose sheets. 
This functionalisation method was then used to cova-
lently bind the growth factors, BDNF and GDNF to BC. 
Our results show that the functionalisation of BDNF 
and GDNF increases the number of cells that grow and 
differentiate on functionalised cellulose scaffolds into 
dopaminergic neuronal progenitors expressing LMX1 
(LIM-homeodomain 1) and FOXA2 (Forkhead box 
protein).
Overall, this work presents a first step in the develop-
ment of biofunctionalised bacterial cellulose as a cell 
scaffold for potential use in cell replacement therapies, 
such as neural grafting of human embryonic stem cell-
derived dopaminergic neurons in Parkinson’s disease 
patients.
Methods
The production of bacterial cellulose
The wildtype bacterium strain Gluconacetobacter hense-
nii was used following the method described by Hestrin 
and Schramm [17]. For the preparation of bacterial cul-
tures, 500 mL Hestrin and Schramm (H–S) medium was 
made in  H2O containing (w/v): 0.5% yeast extract, 0.5% 
peptone, 0.27%  Na2HPO4 dibasic, 0.15% citric acid and 
2% glucose (added following autoclaving), at pH 6. For 
culturing in liquid solution, 5  mL of H–S medium was 
added to a 50-mL falcon tube; triplicates of G. hensenii 
culture were selected and kept at 30 °C for 7 days. For cel-
lulose production, 100 µL of bacterial culture was added 
to a petri dish of 5  mL H–S medium and incubated at 
30  °C for 2  weeks. For cleaning, cellulose was removed 
from the cell solution and washed several times with 
 dH2O. Cellulose was then purified with 0.1–1 M NaOH 
at 70 °C for 2 h during which the cellulose changed colour 
to off-white/colourless. Cellulose was washed with  dH2O 
until the pH reached pH 7. The cellulose was freeze-dried 
for longer-term storage and kept in  dH2O or PBS [43].
The preparation and biofunctionalisation of bacterial 
cellulose
In this study, we used freeze-dried macrosheets instead 
of the never-dried or the nanofibre forms of BC.
The ‘conventional’ method for the silanisation of 
cellulose fibres described by Salon et  al. [42] is com-
posed of two steps, hydrolysis and condensation. (1) 
Hydrolysis of 5% (3-Glycidyloxypropyl)trimethoxysilane 
(GPTMS, > 98%, Sigma-Aldrich, St. Louis, USA) was 
achieved in 80:20 v/v isopropanol:water for 2 h at room 
temperature. After 10 min, the cellulose was added, and 
the mixture was placed on a shaker. This permitted the 
adsorption of the silanol through acid–base bonding to 
the hydroxyl groups of cellulose. (2) Chemical condensa-
tion was ensured by heating to 120  °C using a hot plate 
until dry (~ 5 min) and results in the formation of silox-
ane bridges. The protein used for functionalisation, in 
this case Alexa Fluor® 488-conjugated goat anti-rabbit 
IgG (ab150077, Abcam, Cambridge, UK), can then be 
placed in contact with the dried, cooled cellulose surface 
for ~ 4 min before washing 3 × in PBS.
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The ‘aqueous one-pot silanisation’ method was first 
described by Beaumont et al. [3, 4]. In this method, cel-
lulose is placed in  H2O and acidified with 1% v/v 0.5 M 
HCl to achieve the hydrolysis. To this, 0.5% v/v GPTMS 
(> 98%, Sigma-Aldrich) is added and shaken for 30 min. 
Following this initial treatment, 2% v/v 0.5  M NaOH is 
added for a further 2 h to induce the condensation. Cellu-
lose is removed and washed 1 × with acetone and briefly 
dried under nitrogen before the addition of a model 
protein, Alexa Fluor® 488-conjugated goat anti-rabbit 
IgG (ab150077, Abcam). After ~ 5 min, excess protein is 
removed from the cellulose by washing it 3 × with PBS.
Following the procedure for the aqueous one-pot 
silanisation method, laminin is added to cellulose at 
2 µg/mL concentration in Hanks’ Balanced Salt Solution 
(HBSS; Sigma-Aldrich). In addition to laminin, cellulose 
sheets were biofunctionalised with growth factors BDNF 
(Sigma-Aldrich) at 8 µg/mL and GDNF (Sigma-Aldrich) 
at 4  µg/mL. To determine whether the functionalisa-
tion method affects the cell growth, 20  µg/mL laminin 
(Sigma-Aldrich) was added to plastic wells (96 multiwell 
plate, Corning®, Sigma-Aldrich) containing bacterial cel-
lulose, without the biofunctionalisation step. All samples 
are incubated overnight before washing 3x ~ 5 min with 
HBSS.
Culturing and plating of human embryonic stem 
cell‑derived progenitor cells
RC17 (Roslin Cells, cat. no. hPSCreg RCe021-A) cells 
were maintained in iPS brew XF (Miltenyi, Bergisch 
Gladbach, Germany) on laminin-521 (0.5 µg/cm2 Biolam-
ina LN-521)-coated plates and were patterned towards a 
ventral midbrain fate as described in Nolbrant et al. [37]. 
In brief, differentiation of hESCs to dopaminergic pro-
genitors is a 16-day protocol. For neuralisation, the hES 
cell colonies were detached with EDTA (0.5 µM/ml) and 
plated at 10,000 cells/cm2 on laminin (Sigma-Aldrich)-
coated plates in N2 medium (DMEM/F12:Neurobasal 
(1:1), N2 supplement (1:100), ROCK inhibitor (Y-27632, 
10 µM, Tocris Bioscience, Bristol, UK), SB431542 (10 µM, 
Tocris Bioscience) and Noggin (100  ng/ml, R&D), and 
for patterning to ventral mesencephalic fate, SHH-C24II 
(300 ng/ml, Miltenyi) and 0.85 µM CHIR99021(Miltenyi) 
were added to the medium from day 0–9. On day 9, the 
cells were grown in N2 medium supplemented with 
FGF8b (100  ng/ml, Miltenyi). On day 11 of differen-
tiation, the cells were dissociated to single cells with 
accutase (75  µl/  cm2, Thermo Fisher) and replated onto 
lam-111 coated/bacterial cellulose plates at 800,000 cells/
cm2 in B27 medium (Neurobasal, B27 supplement with-
out vitamin A (1:50), brain-derived neurotrophic factor 
(BDNF) (20 ng/ml, Miltenyi), glial cell line-derived neu-
rotrophic factor (GDNF) (10  ng/ml, Miltenyi), FGF8b 
and ascorbic acid (200  mM, Tocris Bioscience). Cells 
grown on functionalised bacterial cellulose contained 
B27 medium with FGF8b and ascorbic acid alone.
MTS cell proliferation assay
The MTS cell proliferation assay was based on the 
instructions provided (CellTiter 96®  AQueous One Solu-
tion Cell Proliferation Assay (MTS), Promega, Madi-
son, USA). In brief, 20  µL MTS solution was added to 
DIV3 (days in  vitro) cells in 100  µL of culture medium 
and incubated for 1 h at 37 °C at 5%  CO2. Absorbance at 
490 nm was measured using a 96 multiwell plate reader 
(Envision 2104 Multilabel Reader, PerkinElmer, Waltham, 
USA).
Imaging and quantifying the growth of neural stem cells
Cells were fixed in 4% paraformaldehyde for 10  min at 
room temperature and washed 3 × in 37  °C PBS. After-
wards, the cells were incubated in blocking solution com-
posed of PBS, 0.2% Triton-X and 4% donkey serum for 
1 h at 4 °C. Primary antibody, anti-FOXA2 (R&D Systems 
AF2400) and anti-LMX1 (Merck Millipore, AB10533) 
were added 1:100 into the blocking solution (PBS, 5% 
donkey serum, 0.1% Triton X10), and the cells were incu-
bated for 2 h at room temperature. Samples were washed 
in 3 × blocking solution before the addition of 1:500 don-
key anti-goat IgG secondary antibody, Alexa Fluor® 561 
(Thermo Fisher Scientific, Waltham, USA) and 1:500 
donkey anti-goat IgG (H + L) secondary antibody, Alexa 
Fluor® 647 (Thermo Fisher Scientific) to the cells for 1 h 
at room temperature. Samples were washed 3 × in block-
ing solution , and 1 × in PBS. 1:1000 Hoechst 33,342 (Inv-
itrogen, Thermo Fisher Scientific) was added to the cells 
in PBS before imaging them.
Samples were imaged using a custom-made widefield 
microscope with an Olympus frame (IX83, Olympus, 
Tokyo, Japan) and automated stage (Prior, Fulbourn, UK), 
plasma light source (HPLS343, Thorlabs, Newton, USA) 
and camera (Clara interline CCD camera, Andor, Belfast, 
UK) with filter sets for DAPI (49,000–ET–DAPI, Chroma 
Technology, Bellows Falls, USA), Alexa Fluor® 561 
(49,008–ET–mCherry, Texas Red®, Chroma Technology) 
and Alexa Fluor® 647 (676/29  nm emission filter, Sem-
rock, Rochester, USA). Pre-processing of images included 
background subtraction and intensity thresholding in 
ImageJ [41]. Counting was performed manually.
Statistical methods
Data visualisation and statistical analysis were per-
formed with GraphPad Prism 6.0 software (Graph-
pad, La Jolla, USA). All numerical data are expressed 
as mean ± standard deviation (SD) unless stated 
otherwise. Results (n ≥ 3 in all cases, unless stated 
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otherwise) were analysed by unpaired, two-tailed t 
tests for 2 experimental groups, or by one-way analy-
sis of variance (ANOVA) with multiple comparisons for 
3 + groups of data. P values < 0.05 were considered sta-
tistically significant.
Results
Bacterial cellulose can readily be functionalised 
with growth factors
The conventional strategy uses 3-glycidopropyltri-
methoxysilane (GPTMS) binding and high temperature 
Fig. 2 A comparison of two methods for the biofunctionalisation of bacterial cellulose with a model protein shows improved results for the 
‘one pot’ method. A Both conventional (left) and aqueous one-pot (right) strategies were used to prepare glycido-coated cellulose through 
silanisation followed by covalent adherence of protein. AlexaFluor®-488-conjugated antibody immobilised onto the cellulose modified by (B1) 
conventional method results in cracking of protein, as shown by arrows but not in (B2) using the ‘aqueous one pot’ method. Surface fluorescence 
intensity profiles show an increase in intensity in regions where AlexaFluor®-488-conjugated antibody has covalently bound to cellulose (C1, C2 
representing conventional and aqueous one pot strategy, respectively). The fluorescence map was obtained by plotting the intensity profile of the 
conjugated antibody attached to BC
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curing, and the one-pot strategy is in aqueous condi-
tions (Fig.  2A). Both resulted in glycido-functional-
ised cellulose, which can successfully be employed 
for protein immobilisation through amine groups. 
AlexaFluor®-488-labelled antibody was used as a model 
protein to assess the applicability of each strategy 
(Fig. 2B, C).
The fluorescence intensity profile across the function-
alised area (Fig. 2C1, C2) shows a more uniform func-
tionalisation of the protein in Fig.  2C2 as compared 
to in Fig.  2C1, where cracks in the protein are visible. 
As the functionalised scaffolds are inserted into the 
wet environment of the brain, it is important that the 
method is compatible with rehydration and there is no 
damage to the scaffold upon insertion. If scaffold break-
age was to occur once the implant is inserted, this could 
result in an uneven distribution of the protein, clumps 
of composite material and even physiological micro-
damage, which might have significant negative conse-
quences. For this reason, the ‘aqueous one-pot’ method 
was selected as a method of choice for further func-
tionalisation of BC sheets and stem cell differentiation.
Functionalised bacterial cellulose is fully biocompatible
Following the optimisation of the functionalisation 
protocol using an antibody, BC was next functional-
ised with laminin alone or with laminin and the growth 
factors (GFs) BDNF and GDNF. These were employed 
with the aim to determine whether they support the 
proliferation and maturation of human embryonic stem 
(ES) cell-derived ventral midbrain (VM) progenitor 
cells [25, 37], and improve the growth of these cells on 
BC. Laminin is required for cell survival and was used 
in all tested samples. VM progenitor cells were plated 
on to laminin-coated 96 multiwell plates (Lam-wells), 
laminin-coated cellulose (Lam-coat), cellulose func-
tionalised with laminin (Lam-cov), and cellulose func-
tionalised with laminin and both of the growth factors, 
BDNF and GDNF (Lam-GFs-cov). Shown in Fig. 3 are 
MTS assays, a colorimetric assay for measuring cell 
metabolic activity, performed to assess the cell viability.
The results, as seen from MTS assay data obtained 
for functionalised laminin + BDNF + GDNF (Lam-
GFs-cov) or functionalised laminin only (Lam-cov), 
show that there are no differences in the viability of 
hES-derived VM progenitor cells plated on different 
substrates, nor was the cell viability affected by the 
functionalisation of cellulose. Although the MTS assay 
clearly shows that bacterial cellulose does not affect the 
growth and survival of cells, it is important to deter-
mine whether it maintains the identity of VM progeni-
tor cells.
The cellulose scaffold supports the expression 
of dopaminergic transcription factors in VM progenitors
After we showed that culturing VM progenitors on bac-
terial cellulose did not affect their survival, experiments 
were performed to determine whether different scaffolds 
supported the caudalisation and proliferation of VM pro-
genitor cells. The transcription factors FOXA2 (Fig. 4A) 
and LMX1 (Fig. 4B) were used as markers of VM progen-
itor identity. The proportion of cells expressing FOXA2 
or LMX1 was calculated, alongside the proportion of 
cells expressing both transcription factors.
BC coated with laminin supports differentiation of 
stem cells to dopaminergic precursors as shown by 
FOXA2 and LMX1 expression. Expression of FOXA2 
is similar in cells grown on plastic and BC. However, as 
shown in Fig.  4, there is a reduction in number of cells 
expressing LMX1 and LMX1 colocalised with FOXA2.
We were then interested to investigate whether the 
functionalisation of either laminin, or laminin with GFs 
would further support the growth and differentiation.
As shown in Fig. 5, the functionalisation of cellulose 
with laminin, BDNF and GDNF increases the number 
of cells that express the transcription factors LMX1 
(Fig. 5B), and colocalised FOXA2 and LMX1 (Fig. 5C) 
in nuclei as compared with laminin–cellulose alone. 
Fig. 3 MTS assay shows there is no difference in the viability of 
hES-derived VM progenitor cells plated on plastic (open circles) or 
cellulose. Values represent absorbance at 490 nm as normalised 
to laminin coated plastic (Lam-wells). The functionalisation 
method requiring covalent binding of peptides to cellulose has 
no negative effects on the cell metabolism, as seen from MTS 
assay data obtained for functionalised laminin + BDNF + GDNF 
(Lam-GFs-cov) or functionalised laminin only (Lam-cov); one-way 
analysis of variance (ANOVA); P = 0.7883; F (3, 8) = 0.3532. Tukey’s 
multiple comparison P values (Laminin (A), cellulose + laminin (B), 
cellulose + functionalised laminin (C), cellulose + functionalised GFs 
(D): (A–B) not significant (NS) = 0.8655; (A–C) NS = 0.8634; (A–D) 
NS ≥ 0.9996; (B–C) NS ≥ 0.9999; (B–D) NS = 0.9041; (C–D) NS = 0.9023). 
Experiments were performed from N = 3 experimental repeats with 
n = 3 technical repeats. Mean values ± standard deviation are plotted
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This suggests that the biofunctionalisation of these 
growth factors increases the maturation of stem cells 
into the dopaminergic neuronal lineage.
However, the functionalisation of laminin alone does 
not increase the expression of FOXA2 and LMX1 sig-
nificantly above that seen on the laminin-coated cellu-
lose sample.
These results support our hypothesis that BC can be 
employed as a scaffold for differentiation of embry-
onic stem cells and that GF-functionalised BC further 
improves the expression of early dopaminergic markers 
in these cells.
Discussion
In this work, we have optimised a method to biofunc-
tionalise bacterial cellulose sheets with growth factors 
and use them as cell scaffold that may, once proven suc-
cessful in  vivo, become useful for the implantation of 
stem cells into patients. Studies on human embryonic 
stem cells (hESC) demonstrated that the BC scaffold sup-
ports differentiation of these stem cells to dopaminergic 
VM progenitor cells which are used for cell replacement 
therapies in Parkinson’s disease. The functionalisation 
of the scaffold with laminin, and growth factors BDNF 
and GDNF further increased the proportion of cells that 
Fig. 4 hES-derived VM progenitors grown on bacterial cellulose express markers of dopaminergic lineage. VM progenitors grown on laminin 
coated bacterial cellulose (Lam-coat) express FOXA2, LMX1, and FOXA2 and are colocalised with LMX1. The expression of FOXA2 is comparable 
to the plastic substrate controls (Lam-wells). The expression of LMX1 and LMX1 with FOXA2 is decreased compared with cells cultured on plastic. 
The proportion of cells showing colocalisation of a nuclear marker, Hoechst 33,342 (blue) with the transcription factor A FOXA2 (magenta); B LMX1 
(yellow); C FOXA2 (magenta) and LMX1 (yellow). Two-tailed unpaired Student’s t test were used for statistical analysis. ***P < 0.001. Experiments were 
performed from N = 3 experimental repeats with n = 3 technical repeats. All data are plotted with mean values ± standard deviation normalised to 
Laminin coated plastic (Lam-wells). Scale bar: 30 µm
Page 9 of 12Robbins et al. Stem Cell Res Ther          (2021) 12:574  
differentiate once plated on BC. Such covalent attach-
ment of GFs can prevent leakage of the protein and pro-
vide cells with long-term supply of GFs necessary for 
successful differentiation and growth of VM progenitor 
cells. In addition, covalent GF-functionalisation is also 
highly cost-effective as it reduces the concentration of 
growth factors that need to be exogenously added to the 
medium during cell culture.
Biofunctionalisation of cellulose was based on pre-
viously reported strategy employing salinisation of 
cellulose fibres and nanocellulose, but needed to be 
adapted to large sheets of freeze-dried BC [3, 4]. Previ-
ously developed silanisation methods of cellulose used 
‘never-dried’ or nanofibre forms of cellulose, as opposed 
to freeze-dried macrosheets. We therefore tested two 
methods of silanisation, the ‘conventional’ and the ‘one-
pot’ method to determine whether they could be used for 
freeze-dried cellulose. Although the conventional ‘curing’ 
method required fewer steps, it resulted in hornification, 
temporary cellulose shrinkage and crosslinking of the 
Fig. 5 Growth of stem cells on GF-functionalised bacterial cellulose further increases the expression of FOXA2, LMX1, and FOXA2 colocalised 
with LMX1 compared to laminin only coated cellulose samples. The percentage of cells showing co-localisation of a nuclear marker, Hoechst 
33,342 (blue) with the transcription factor A FOXA2 (magenta); B LMX1 (yellow); C FOXA2 (magenta) and LMX1 (yellow), as determined by manual 
counting. A (one-way analysis of variance (ANOVA); P = 0.1090; F (2, 43) = 2.145). Tukey’s multiple comparison P values [Lam-coat (A), Lam-cov (B), 
Lam-GFs-cov (C)]: A, B not significant (NS) = 0.8503; A–C NS = 0.1065; B, C NS = 0.2894. B (one-way analysis of variance (ANOVA); *P = 0.0116; F (2, 
40) = 1.961) Tukey’s multiple comparison P values [Lam-coat (A), Lam-cov (B), Lam-GFs-cov (C)]: A, B not significant (NS) = 0.1200; A–C **P = 0.0093; 
B, C NS = 0.4905. C (one-way analysis of variance (ANOVA); **P = 0.0044; F (2, 34) = 2.152). Tukey’s multiple comparison P values [Lam-coat (A), 
Lam-cov (B), Lam-GFs-cov (C)]: A, B not significant (NS) = 0.1200; A–C **P = 0.0030; B, C NS = 0.2250
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trivalent silanol. This in turn resulted in cracking of the 
functionalised protein layer during rehydration in PBS 
(Fig. 2B1) [1, 3, 4]. The conventional method is therefore 
not ideally suited for the preparation of uniformly coated 
and stable cellulose samples. In contrast, the ‘aqueous 
one-pot silanisation’ method [3, 4] does not lead to frac-
tures in the protein layer following the full rehydration in 
PBS (Fig. 2B2).
Despite the current study highlighting the potential of 
BC scaffolds for potential use in cell replacement thera-
pies, it first needs to be tested in vivo, and it needs to be 
confirmed that is does not cause an immune response. 
There are, however, some promising studies already pub-
lished that claim that BC is non-immunogenic and has a 
high biocompatibility [16, 22, 23, 35]. Moreover, future 
work will also need to explore the delivery strategies as 
well as the degradation pathways post-implantation in 
more detail. Importantly, however, the human body does 
not contain cellulases responsible for the natural degra-
dation of bacterial cellulose, which may help to maintain 
its mechanical stability and chemical integrity. However, 
various other oxidative processes and reactive oxygen 
species might cause partial degradation [32, 33], and 
thus, further studies on how quickly BC may be degraded 
in vivo are needed. Recent studies have also focused on 
the design of various bacterial cellulose composites that 
might introduce higher stability and a controlled degra-
dation in  vivo [32, 33]. All of these developments make 
bacterial cellulose a highly interesting material for use in 
neuronal prosthetics, and our study forms an important 
first step towards the design of fully functional BC-based 
scaffolds.
It should also be noted that the functionalisation of 
cellulose is not limited to the proteins used in this study, 
but can be substituted with any other protein or small 
molecule of interest providing they contain an available 
amine group. While in this study we have not character-
ised the degradation or release rate of the GFs from BC, 
we are currently working on functionalisation of the cel-
lulose with immunosuppressants using cleavable linkers 
to enable slow, controllable release. The introduction of 
such moieties would protect implants from an immune 
response from the cells during initial transplantation 
into the brain. In addition, the attachment of proteins 
and small molecules to the cellulose can also provide sig-
nalling functionalities both in  vitro and once implanted 
into the brain, particularly if such molecules are attached 
using cleavable linkers and thus can diffuse into the brain 
tissue from the site of implantation [20, 50].
The advantage of this described functionalisation 
strategy lies in its compatibility with the design of vari-
ous nano-composite structures. For example, various 
nanoparticle binding linkers can be inserted to act as 
anchoring sites for conductive nanostructures such as 
carbon nanotubes to result in conductive scaffolds that 
can enable electrical stimulation and restoring signals 
in electrogenic tissue. The favourable mechanical and 
physiochemical properties of bacterial cellulose, ease of 
preparation and biofunctionalisation make it a highly 
interesting material for use in neuronal implants and 
regenerative medicine in general. As bionanotechno-
logical tools develop further, design of nanocomposites 
will provide us with cellulose material that might have 
enhanced thermal and conductive properties, useful for 
cell differentiation and in  vivo biosensing. We would 
like to encourage the researchers working in the field to 
explore this material further to enrich the material tool-
box and provide clinically transferable solutions.
Conclusions
We have shown that bacterial cellulose (BC) scaffolds can 
be prepared and functionalised to support the differen-
tiation of neuronal stem cells and in such a way be used 
for the development of a new generation of neuronal 
implants. To achieve this, we optimised the Beaumont 
protocol (aqueous one-pot silanisation) [3, 4] to obtain 
an adaptable strategy that can be used for immobilisation 
of a wide range of bioactive peptides or small molecules 
onto BC, which, once proven successful in  vivo, may 
enhance implant efficacy. Using a cell viability assay, we 
have also shown that there is no measurable toxicity of 
the scaffold material and no detrimental effects to stem 
cell differentiation. The proportion of cells that differen-
tiate into neuronal cells once plated on BC was further 
increased by the functionalisation of the scaffold with 
laminin, and growth factors BDNF and GDNF.
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